{"filing":{"accession_number":"0001213900-26-082564","cik":"0001611842","ticker":"PYPD","company_name":"PolyPid Ltd.","form":"6-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"ea0299642-6k_polypid.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611842/000121390026082564/ea0299642-6k_polypid.htm"},"events":[{"id":21463,"run_id":19359,"accession_number":"0001213900-26-082564","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"PolyPid announced FDA acceptance of its NDA for D-PLEX100 with Priority Review status and an accelerated PDUFA target action date of November 28, 2026. This is a material regulatory milestone that triggers a $15 million milestone payment from commercial partner Azurity and represents significant progress toward potential market approval. While this is a regulatory/operational event rather than a discrete financial event (earnings, debt, M\u0026A), it materially affects investor assessment of the company's development trajectory and near-term commercialization prospects.","company_name":"PolyPid Ltd.","ticker":"PYPD","filing_date":"2026-07-29","form":"6-K","submitted_at":null,"items":[{"id":21113,"accession_number":"0001213900-26-082564","item_number":"EX-99.1","item_title":"ea029964201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"PolyPid announced FDA acceptance of its NDA for D-PLEX100 with Priority Review status and an accelerated PDUFA target action date of November 28, 2026. This is a material regulatory milestone that triggers a $15 million milestone payment from commercial partner Azurity and represents significant progress toward potential market approval. While this is a regulatory/operational event rather than a discrete financial event (earnings, debt, M\u0026A), it materially affects investor assessment of the company's development trajectory and near-term commercialization prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T12:36:39.233666+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21113,"accession_number":"0001213900-26-082564","item_number":"EX-99.1","item_title":"ea029964201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"PolyPid announced FDA acceptance of its NDA for D-PLEX100 with Priority Review status and an accelerated PDUFA target action date of November 28, 2026. This is a material regulatory milestone that triggers a $15 million milestone payment from commercial partner Azurity and represents significant progress toward potential market approval. While this is a regulatory/operational event rather than a discrete financial event (earnings, debt, M\u0026A), it materially affects investor assessment of the company's development trajectory and near-term commercialization prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T12:36:39.233666+00:00","company_name":"PolyPid Ltd.","ticker":"PYPD","filing_date":"2026-07-29"}]}